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Abstract
Mixed-lineage-leukemia (MLL) fusion oncogenes are intimately involved in acute leukemia and secondary therapy-related
acute leukemia. To understand MLL-rearranged leukemia, several murine models for this disease have been established.
However, the mouse leukemia derived from mouse hematopoietic stem cells (HSCs) may not be fully comparable with
human leukemia. Here we developed a humanized mouse model for human leukemia by transplanting human cord blood-
derived HSCs transduced with an MLL-AF10 oncogene into a supra-immunodeficient mouse strain, NOD/Shi-scid, IL-2Rc
2/2
(NOG) mice. Injection of the MLL-AF10-transduced HSCs into the liver of NOG mice enhanced multilineage hematopoiesis,
but did not induce leukemia. Because active mutations in ras genes are often found in MLL-related leukemia, we next
transduced the gene for a constitutively active form of K-ras along with the MLL-AF10 oncogene. Eight weeks after
transplantation, all the recipient mice had developed acute monoblastic leukemia (the M5 phenotype in French-American-
British classification). We thus successfully established a human MLL-rearranged leukemia that was derived in vivo from
human HSCs. In addition, since the enforced expression of the mutant K-ras alone was insufficient to induce leukemia, the
present model may also be a useful experimental platform for the multi-step leukemogenesis model of human leukemia.
Citation: Moriya K, Suzuki M, Watanabe Y, Takahashi T, Aoki Y, et al. (2012) Development of a Multi-Step Leukemogenesis Model of MLL-Rearranged Leukemia
Using Humanized Mice. PLoS ONE 7(6): e37892. doi:10.1371/journal.pone.0037892
Editor: Kevin D. Bunting, Emory University, United States of America
Received February 24, 2012; Accepted April 30, 2012; Published June 20, 2012
Copyright:  2012 Moriya et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported in part by a grant-in-aid (#111020001010004100) for scientific research from the Japan Society and Technology Agency, by a
grant from Japan Science and Technology Agency, and by a grant from Kato Memorial Bioscience Foundation. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ishiin@med.tohoku.ac.jp
Introduction
Chromosomal translocations that result in MLL (mixed-lineage
leukemia)-fusion oncogenes are associated with acute myeloid
leukemia (AML), acute lymphoblastic leukemia (ALL), myelodys-
plastic syndrome, and secondary therapy-related acute leukemia
[1]. More than 60 partner genes that form MLL-fusion oncogenes
have been identified [2], and the partner usually characterizes the
specific pathological phenotype of the MLL-rearranged leukemia.
For example, MLL-rearranged AMLs, more than 60% of which
involve the MLL-AF9, MLL-AF10, or MLL-AF6 fusion gene,
often exhibit the morphological subtypes acute myelomonoblastic
leukemia and monoblastic leukemia, which are classified as
French-American-British (FAB) M4 and M5, respectively [3].
Although patients with MLL-rearranged leukemia usually show a
poor prognosis and are sometimes resistant to therapy [3,4], the
development of efficient therapies targeting the MLL-fusion genes
has been slow, in part because much is still unknown about the
cellular and molecular mechanisms underlying this disease.
To gain insight into the etiology and pathogenesis of MLL-
rearranged leukemia, several mouse models have been developed.
Mice with a knocked-in MLL-AF9 fusion gene develop AML as
they age [5], although in humans the congenital MLL-AF9
rearrange typically affects infants. Leukemia has also been
generated in mice by exogenously expressing an MLL-fusion gene
in the animals or by transplanting mouse hematopoietic stem cells
(HSCs) that have been retrovirally transduced with an MLL-fusion
gene [6]. However, the phenotype and pathogenesis of the
leukemia produced in these murine models sometimes do not
match those observed in human leukemia associated with the same
genetic lesion. For example, the MLL-ENL fusion gene is
frequently associated with B-precursor ALL in humans, but
generates AML in mice [7]. Thus, there is a gap in our
understanding about mouse versus human leukemogenesis, and
further leukemia modeling studies using human primary leukemia
cells are needed [8].
In vivo studies in which primary human leukemia cells were
transplanted into immunodeficient mice, provided significant
advances in our understanding of the pathogenesis of human
leukemia [9,10]. However, these models, in which the leukemia
cells had already developed in human patients before being
transplanted into mice, are not suitable for studying physiological
leukemogenesis, including the initiation and progression processes
since these processes do not occur in the model. Therefore, a new
experimental model for analyzing leukemogenesis in which
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hits is needed.
In the past two decades, a number of studies have tried to graft
human HSCs into immunodeficient mice, but these attempts to
reconstitute human blood cells in mice have failed [11]. However,
the recent development of a new immunodeficient mouse strain
has opened up the possibility for generating better xenotransplan-
tation systems. NOD/SCID mice with a targeted mutation of the
IL-2-receptor c chain gene (NOD/Shi-scid IL-2Rc
2/2 (NOG)
and NOD/LtSz-scid IL-2Rc
2/2 (NSG) mice) lack T, B, and NK
cells and some innate immunity functions [11,12]. When human
HSCs are transplanted into these mice, human T, B, NK, and
dendritic cells develop normally and are maintained in the mice
for at least 10 months[13–17]. Thus, these immunodeficient mice
may be good recipients for examining, not only the normal
development of human HSCs, but also their abnormal develop-
ment, including leukemogenesis. Two previous studies modeled
the initiation and progression of human acute leukemia by
ectopically expressing MLL-fusion genes in human HSCs, and
transplanting these cells into special immunodeficient mice
[18,19]. Dick et al demonstrated that ectopic expression of AF9
or MLL-ENL in human HSCs caused leukemia in NOD/SCID
mice in which the NK cells were depleted by an anti-NK cell
antibody [18]. Similarly, Mulloy et al successfully modeled acute
leukemia by transducing MLL-AF9 into human HSCs, and
transplanting these cells into NOD/SCID mice that expressed
transgenic human SCF, GM-CSF, and IL-3 genes [19]. However,
in a similar model using NSG mice, the enforced expression of
MLL-AF4 in HSCs did not induce leukemia [20].
Despite intensive studies on MLL-ENL, MLL-AF4, and MLL-
AF9, there has been no report investigating the in vivo oncogenic
potential of MLL-AF10 in human HSCs, even though MLL-AF10
is the second most common MLL rearrangement (13%) in
pediatric MLL-rearranged AML [3]. Here, using NOG mice,
we demonstrated that MLL-AF10 could enhance the multilineage
hematopoiesis of human HSCs, even though the MLL-AF10 in
mouse HSCs preferentially enhances myeloid differentiation
[21,22]. More importantly, the co-transfection of MLL-AF10
with an active form of the K-ras gene induced acute monoblastic
leukemia with the FAB M5 phenotype. These results provide a
novel leukemia model using human cells showing the requirement
of two genetic hits for leukemogenesis.
Methods
All procedures were performed according to the protocols
approved by the Institutional Committee for Use and Care of
Laboratory Animals of Tohoku University, which was granted by
Tohoku University Ethics Review Board (No. 2010MA165) and
the Guide for Care and Use of Laboratory Animals published by
the U.S. National Institutes of Health (NIH publication 85-23,
revised 1996).
CD34
+ Hematopoietic Stem Cell Isolation
Cord blood from full-term human deliveries was obtained from
the Miyagi Cord Blood Bank (Miyagi, Japan) and RIKEN
Bioresource Center Cell Bank (Tsukuba, Japan), following the
institutional guidelines approved by the Tohoku University
Committee on Clinical Investigations. Mononuclear cells were
isolated from the cord blood by density gradient centrifugation
using Lymphocyte Separation Medium (MP Biomedicals, Solon,
OH, USA) after removing the phagocytes with silica (Immuno
Biological Laboratories, Takasaki, Japan). The cells were washed
and suspended in PBS containing 2%FCS. CD34
+ stem cells were
obtained by magnetic cell sorting (MACS) (Miltenyi Biotech,
Bergisch Gladbach, Germany). Briefly, CD34
+ cells were labeled
with a biotin-conjugated anti-human CD34 monoclonal antibody
(Serotec, Oxford, UK) after blocking the Fc receptor. The cells
were then incubated with anti-biotin Microbeads (Miltenyi
Biotech). The magnetically labeled CD34
+ cells were purified
twice on LS columns (Miltenyi Biotech). The purity of the CD34
+
fraction was .95%. The purified CD34
+ cells were suspended in
Cell Banker (Juji Field, Tokyo, Japan) and cryopreserved at
280uC in a deep freezer until use.
Plasmid Construction
The retroviral vector, pDLNsam-IRES-EGFP, which is based
on Murine Stem Cell Virus with enhanced green fluorescent
protein (EGFP) as a marker under an internal ribosomal entry site
(IRES), was kindly provided by Dr. Masafumi Onodera (Tsukuba
University) [23]. PLAT-F, a package cell line that produces a
pseudotype virus with an RD114 envelope, was previously
established and provided by Dr. Toshio Kitamura (Institute of
Medical Science, University of Tokyo) [24]. The human MLL-
AF10 cDNA [22], which was kindly provided by Dr. M.L. Cleary
(Stanford University), was inserted into a cloning site in the
pDLNsam-IRES-EGFP vector to make the pDLNsam-MLL-
AF10 plasmid. To construct the pDLNsamIRES VENUS vector,
the EGFP cDNA of the retroviral vector was replaced with Venus
cDNA [25], which was provided by Dr. Hiroyuki Miyoshi
(RIKEN, Tsukuba). The human flag-tagged K-ras
G12V cDNA,
which was previously described [26], was inserted into the Xho I
site in the cloning site of pDLNsamIRES Venus to make
pDLNsam-K-ras
G12V.
Gene Delivery into CD34
+ Cells by Retrovirus
The CD34
+ cells isolated from cord blood were cultured in X-
VIVO15 (Cambrex Bioscience, Walkersville, MD, USA), supple-
mented with 1% human serum albumin (HSA) (Kaketsuken,
Kumamoto, Japan) and stimulated with a cytokine cocktail
[100 ng/ml stem cell factor, 100 ng/ml Flt-3 ligand, 100 ng/ml
thrombopoietin, and 100 ng/ml IL-6 (Peprotech)] in a 24-well
plate (2610
5 per well) for 48 h. The stimulated CD34
+ cells were
then harvested and placed into non-tissue culture-treated 6-well
plates (Becton Dickinson) that had been coated with 20 mg/ml
CH-296, a recombinant fibronectin fragment (Retronectin,
Takara, Japan). (3610
5 cells per well) in the presence of the
respective virus supernatant. The virus supernatants were diluted
1:2 with X-VIVO15 containing 1% HSA and the cytokine cocktail
described above. Every 12 h, the medium was replaced with fresh
virus supernatant. After 48 h of culture, the frequency of GFP-
and/or Venus-expressing CD34
+ cells was examined by FACS.
Cell Transplantation into Mice
NOD/Shi-scid, IL-2Rc
2/2 (NOG) mice were obtained from
the Central Institute for Experimental Animals (CIEA, Kawasaki,
Japan) and maintained in an animal facility at Tohoku University
Graduate School of Medicine under specific pathogen free
conditions. All procedures were performed according to the
protocols approved by Tohoku University Ethics Review Board
(No. 2010MA165). Neonatal (1–3 days) NOG mice were
irradiated with 30 cGy of X-rays, and the cultured CD34
+ cells
(1.021.5610
5)i n7 0ml PBS were intrahepatically injected into the
mice later the same day. From one cord blood sample, donor cells
could be prepared for transplantation into 3 recipient mice.
Therefore, 2 to 4 different cord blood samples were used for each
mouse group. Since even NOG mouse sometimes failed to engraft
human HSCs, 9 recipient mice that had no human CD45
+
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excluded from this study.
Antibodies and Flow Cytometric Analysis
Surface markers were detected with the following fluorescent
human specific antibodies from BD Biosciences, San Jose, CA,
USA: CD33-PE, HLA-DR-PE, CD14-PE, CD19-APC, CD11b-
APC, CD15-APC, and CD45-APC-Cy7. To monitor the recon-
stitution of human blood in NOG mice, peripheral blood was
periodically taken from the tail vein. To examine the spleen, bone
marrow (BM), and liver, single-cell suspensions were prepared
from the spleen and liver by mincing with metal mesh and from
the BM by flushing the tibiae and femurs with PBS containing 2%
FCS, using a 27-gauge needle. The cells were stained with the
relevant antibodies for 15 min on ice, then washed with cold PBS
containing 2% FCS, and stained with the appropriate secondary
antibodies when necessary. After the final wash, the cells were
subjected to flowcytometric analysis with a FACSCanto II
cytometer (BD Biosciences). To distinguish between the EGFP
(510 nm) and Venus (535 nm) fluorescences, an apporopiate
combination of mirrors and optical filters was used. The
proportion of each lineage was calculated using FACS Diva
software (BD Biosciences).
Reverse Transcription-PCR (RT-PCR)
Total RNA was prepared from cells using Trizol Reagent
(Invitrogen, Carlsbad, CA, USA). The concentration of total
RNA was measured by a NanoDrop 1000 (Nanodrop Technol-
ogies Inc., Wilmington, DE, USA), and first-strand cDNA was
synthesized using Superscript II (Invitrogen) with an oligo (dT)
primer. The cDNA for MLL-AF10, Flag-K-ras, or b-actin was
amplified with specific primers using Ex-Taq polymerase
(Takara). The primer sets were as follows; MLL-AF10: forward,
5 `- ccaaaagaaaaggaaaaacca and reverse, 5 `-gacttcagcattcc-
taaaatgtca; Flag-K-ras: forward, 5 `-gactacaaagacgatgacg and
reverse, 5 `-ccctgtcttgtctttgc; b-actin: forward, 5 `-gctcgtcgtcga-
caacggctc and reverse, 5 `-caaacatgatctgggtcatcttctc.
DNA Extraction and Southern Blot Analysis
Genomic DNA was extracted from spleens using the GenE-
lute
TM Mammalian Genomic DNA Miniprep kit (Sigma-Aldrich,
USA). For Southern blot analyses, 10 mg genomic DNA was
digested with BglII (Toyobo, Osaka, Japan) overnight at 37uC and
separated by electrophoresis on a 0.7% agarose gel for 12 h at
40 V. The DNA was transferred overnight to a Hybond N
+
membrane (GE Healthcare, Chalfont St. Giles, UK). The DNA
was fixed onto the membrane with a UV Stratalinker 1800
(Stratagene). The membrane was probed with 10
6 cpm/ml of
[C
32P]dCTP (Perkin Elmer)-labeled EGFP cDNA. This EGFP
probe was derived from a 700-bp ScaI fragment of the pDLNsam-
IRES-EGFP vector, and radiolabeled using a random prime
labeling kit (Takara). The membrane was then washed and
exposed to a BAS-III imaging plate (Fuji Photo Film Co., LTD,
Japan), and the image was produced and analyzed using a BAS-III
software (Fuji Photo Film Co., LTD).
Histopathology
The BM, spleen, and liver were examined macroscopically, and
the spleen was weighed. Tissues were fixed in 10% formalin for at
least 48 hours. Hematoxylin and eosin staining or May-Giemsa
staining was performed on 3-mm sections using a routine protocol.
For CD45 immunostaining, after dewaxing and antigen retrieval
by microwave, the sections were incubated for 1 h with mouse
anti-human CD45 (Dako Japan, Tokyo). Immunodetection was
performed using HRP as the visualization enzyme and DAB as the
substrate chromogen. All slides were examined by light micros-
copy using an Olympus IX50 microscope (Olympus, Tokyo,
Japan) and a SPOT camera.
Statistical Analysis
Data are presented as the mean 6 standard deviation (SD).
Statistical analyses were performed using either a paired or
unpaired Student’s t-test. Statistical significance was defined as a
P-value ,0.01 (**).
Results
Enforced Expression of MLL-AF10 Augmented
Multilineage Hematopoiesis, but was Insufficient for
Leukemogenesis in vivo
To examine the pathogenesis of the MLL-AF10 fusion gene
during the differentiation of human blood cells from HSCs, MLL-
AF10-infected cord blood CD34
+ cells were transplanted intrahe-
patically into sublethally irradiated neonatal NOG mice. None of
the recipient mice showed any sign of disease, such as body weight
loss or the appearance of abnormal peripheral leukocytes, 25
weeks after transplantation (data not shown). The expression of the
transduced MLL-AF10 gene in the reconstituted human blood
cells was confirmed (Figure 1A), indicating that the enforced
expression of MLL-AF10 in human HSCs could not induce any
hematological disorders including leukemia in this model.
However, the MLL-AF10 appeared to augment hematopoiesis.
As shown in Figure 1B, when empty control vector (EV) was
transdused into human CD34
+ HSCs, the frequency of the GFP
+
population did not change significantly (60% before transplanta-
tion and 24% and 48% after transplantation in the spleen and
BM, respectively) (Figure 1B). In contrast, when MLL-AF10 was
exogenously expressed, the GFP
+ population markedly increased
from 2% (before) to 11% (25 weeks after transplantation)
(Figure 1B). Therefore, the MLL-AF10-positive blood cells may
have a growth advantage in vivo compared to the MLL-AF10-
negative normal blood cells (CD45
+GFP
- cells).
We next characterized the lineage composition of the human
CD45
+GFP
+ cells in the BM and spleen of both groups. The GFP
+
MLL-AF10-expressing cells did not show a skewed lineage
differentiation compared to the EV-transfected hematopoietic
Figure 1. Enforced expression of MLL-AF10 augmented multilineage hematopoiesis, but was insufficient to induce leukemogenesis
in vivo. (A) Representative RT-PCR results confirming the long-term expression of the MLL-AF10 transcript in the BM cells of mice 25 weeks after
transplantation (lane 1; water, lane 2; cells from a mouse in the EV-transfused group, lane 3; cells from a mouse in the MLL-AF10-transfused group,
and lane 4; positive control (MLL-AF10 plasmid)). (B) Flowcytometric analysis of the frequency of GFP
+ cells. The indicated vector (EV, left or MLL-AF10,
right)-transduced human CD34
+ cells, whose in vitro GFP expression is shown in the upper panels (Before) of the flowcytometric analysis, were
transplanted into NOG mice. Twenty-five weeks later, the GFP-expressing cells gated on human CD45
+ hematopoietic cells in the BM was measured
(lower panels of the FACS profiles). The data shown are representative of 3 independent experiments. The graphs show the frequency of GFP
+ cells in
human CD34
+ cells just before transplantation (Before) and the mean 6 SD of the frequency of GFP
+ cells in the BM and spleen of mice receiving
transplants of EV-transduced HSCs (n=8) or of MLL-AF10-transduced HSCs (n=6) 25 weeks after transplantation, in one representative experiment of
three. Similar results were obtained in the 3 independent experiments.
doi:10.1371/journal.pone.0037892.g001
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transduced human hematopoietic cells. The human CD45
+ GFP
+ cells were analyzed for their lineage distributions to B cells (CD19
+), T cells (CD3
+),
and myeloid cells (CD33
+). (B) Multilineage differentiation of MLL-AF10-transduced cells. The data shows cells gated on the CD45
+GFP
+ cell
population. The graph represents the mean 6 SD of the frequencies of CD33
+ myeloid cells, CD19
+ B cells, and CD3
+ T cells in the BM (upper) and
spleens (lower) of mice engrafted with EV-transduced (n=8) or MLL-AF10-transduced (n=6) CD34
+ HSCs. No difference in the graft composition
between the EV- and MLL-AF10-expressing CD34
+ HSCs was found. Similar results were obtained in 3 independent experiments.
doi:10.1371/journal.pone.0037892.g002
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mouse HSCs, which showed skewed myeloid differentiation by the
exogenous expression of MLL-AF10 [21,22], the enforced
expression of MLL-AF10 in human HSCs enhanced the
hematopoietic repopulation of HSCs without affecting cell
differentiation.
Co-transduction of Activated K-ras and MLL-AF10 into
CD34
+ HSCs
As described above, transduction of the MLL-AF10 gene alone
was not sufficient to induce leukemogenesis from human HSCs in
the present model. Similarly, Menendez et al recently demon-
strated that the MLL-AF4 gene alone cannot induce leukemia
from human CD34
+ HSCs in a humanized mouse model [20].
These observations prompted us to generate a two-hit model of
leukemogenesis using MLL-AF10 and one additional oncogene.
We thus used the K-ras
G12V oncogene because K-ras
G12V is a very
well-characterized oncogene, and because ras mutations are found
in about 30% of the cases of pediatric MLL-rearranged AML [3].
To evaluate two hits in one cell, we needed to distinguish the
MLL-AF10 and K-ras
G12V expressions. We thus retrovirally
transfected CD34
+ HSCs with MLL-AF10-EGFP and K-ras
G12V
that was co-expressed with the Venus fluorescent protein, which
can be distinguished from EGFP by flowcytometry (Figure 3A).
The MLL-AF10 and K-ras co-infected (GFP
+Venus
+) cells were
quite rare (0.9%) (Figure 3B). Nevertheless, we injected the CD34
+
HSCs, which contained 74% non-transduced, 0.9% MLL-AF10-
alone-transduced, 24% K-ras
G12V-alone-transduced, and 0.9%
co-transduced cells, intrahepatically into NOG mice (Figure 3B).
Cooperation of MLL-AF10 with Activated K-ras Induced
Acute Monoblastic Leukemia
By 8 weeks after transplantation, several mice in the MLL-
AF10/K-ras
G12V co-transduced group showed a rough coat, slow
movement, and weight loss, while no mice in the other groups
(EV, MLL-AF10 alone, and K-ras
G12V alone) demonstrated any
disease manifestations (data not shown). As the mice in the co-
transduced group got sick, most of their peripheral leukocytes
became double positive for GFP and Venus (Figure 4B). In
addition, morphologically identifiable leukemia cells, character-
ized by abnormal nuclei and cytoplasmic vacuoles, were found in
the peripheral blood (Figure 4C). The morphology of the leukemia
cells was compatible with that of the M5 type of FAB classification,
which is relatively common in MLL-rearranged AML. Further-
more, splenomegaly in the mice engrafted with the MLL-AF10/
K-ras
G12V co-transduced human HSCs was observed 8 weeks after
Figure 3. Co-transduction of activated K-ras and MLL-AF10 into CD34
+HSCs. (A) Schematic structure of the MLL-AF10-GFP and Flag-K-
ras
G12V-Venus vectors. (B) Infectious efficiency of the MLL-AF10-GFP and Flag-K-ras
G12V-Venus co-transfection. The data and the summary shown in
the flowcytometric analysis is representative of the transduced CD34
+ HSCs in 2 experiments.
doi:10.1371/journal.pone.0037892.g003
Multi-Step Leukemogenesis Model of Human Leukemia
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e37892Multi-Step Leukemogenesis Model of Human Leukemia
PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e37892transplantation (Figure 4D), and the average weight of their
spleens was 5 times greater than in the other groups (Figure 4D).
By 10 weeks after transplantation, 100% of the mice that had
received MLL-AF10/K-ras
G12V co-transduced HSCs were dead,
while all the mice in the other 3 groups survived and remained
healthy 25 weeks after transplantation (Figure 4A).
We next investigated by FACS the composition of the blood
cells in the BM, spleen, and liver of the MLL-AF10/K-ras
G12V-
expressing HSC-treated mice. Most of the hematopoietic cells in
these tissues were GFP
+ Venus
+ double positive (Figure 5A). The
double-positive cells were confirmed to express both the MLL-
AF10 and K-ras
G12V genes by RT-PCR with specific primers for
the exogenously transduced genes (Figure 5B). Interestingly, no
cells expressing MLL-AF10 alone (GFP
+ Venus
-) or K-ras
G12V
alone (GFP
2Venus
+) were observed in any mice in the co-
transduced group, even though MLL-AF10 alone could effectively
promote multilineage hematopoiesis (Figures 1 and 2). More
importantly, in the group receiving K-ras
G12V alone-transduced
HSCs, there were no Venus
+ K-ras
G12-expressing blood cells in
any tissues examined, even in the BM (data not shown). These
results indicate that the co-expression of MLL-AF10 and K-
ras
G12V (GFP
+Venus
+) was necessary for the in vivo induction of
leukemia from human HSCs.
Additional FACS data showed that the GFP
+Venus
+ human
CD45
+ blood cells in the all recipient mice transfused with the co-
transfected HSCs had a uniform surface marker profile,
CD33
+CD11b
+HLA-DR
+CD14
+CD15
+ (Figure 5C), which was
fully compatible with the FAB M5 phenotype. This finding
suggested that the abnormal blood cells observed in the mice
receiving co-transduced HSCs were leukemia cells. We next
examined the cellular clonality of the abnormal blood cells by
Southern blotting. As shown in Figure 5D, an EGFP probe that
recognizes both EGFP and Venus (because the nucleotide
sequences between EGFP and Venus are 98% identical) revealed
one or two bands in the DNA of the abnormal leukocytes from
individual mice in the co-transduced group, indicating the
monoclonality of the abnormal leukocytes.
Taken together, we have successfully established a human
leukemia model in which acute monoblastic leukemia cells are
derived from human normal HSCs in vivo.
Pathological Phenotypes of the Leukemia
Pathological examination of our human leukemia model
showed that the spleens were extensively infiltrated with human
hematopoietic cells, and the architecture of the red pulp and the
white pulp was disrupted (Figures 6A and 6B). The tibia bones
looked very pale (data not shown), and the BM was occupied by
uniform blood cells, which expressed human CD45 (Figures 6A
and 6B). The periportal regions of the liver were also massively
infiltrated with human hematopoietic cells (Figure 6A and 6B).
Hepatosplenomegaly is a common symptom in patients with acute
monoblastic leukemia with rearranged MLL genes, and leukemia
cell infiltration into the intrahepatic periportal regions is also a
common pathological manifestation of human MLL-rearranged
monoblastic leukemia. Therefore, our model may be a good
representation of human MLL-rearranged monoblastic leukemia.
Discussion
A detailed understanding of leukemogenesis requires the
development of experimental murine models that can accurately
mimic this process. Some studies have sought to recapitulate the
harboring of MLL fusion genes in human AML using mouse
HSCs [6]. However, the leukemia occurring in mice often does not
faithfully recapitulate human leukemia, in part because of the
biological differences between human and mouse HSCs [8,27]. In
two improved models, the MLL-ENL or MLL-AF9 gene was
recently shown to be capable of initiating human leukemogenesis
in NK-cell-depleted NOD/SCID mice [18] or human cytokine
transgenic NOD/SCID mice [19]. However, overexpression of
the MLL-AF4 fusion gene in human CD34
+ cells is not sufficient
to initiate leukemia [20]. Similar to the latter report, we found that
MLL-AF10 was insufficient to induce leukemogenesis at least by
25 weeks after transplantation in the present model. In our
experiments, the infectious efficiency of the MLL-AF10 vector in
human HSCs was low (,2.0%). Although the efficiency of MLL-
ENL and MLL-AF9 in the former report was unclear [18],
differences in the infectious efficiency of the vectors used among
these studies might have been responsible for the different
leukemogenic effects. In another model with MLL-AF9 [19],
human SCF, GM-CSF, and IL-3 were transgenically expressed in
the recipient NOD/SCID mice. These cytokines may provide the
MLL-AF9-transdused HSCs with additional signals for cell growth
and survival, which might work as an oncogenic promoter.
Comparing our model with this model, ectopic expression of K-
ras
G12V in our model may in part compensate the cytokine (SCF,
GM-CSF, and IL-3) signals in the MLL-AF9 model since
stimulation with SCF and cytokines directly activates the ras
signaling pathway in leukemogenesis [28]. However, it is also likely
that each MLL-rearranged gene (MLL-ENL, MLL-AF4, MLL-
AF9, and MLL-AF10) has a different leukemogenic efficacy,
because the different partners of MLL may confer different
biological functions to the produced MLL-fusion molecule [2].
Accumulating evidence points to a multistep pathogenesis for
leukemia development and progression [29,30]. In the multi-
genetic step models of leukemogenesis, particularly in the two-hit
model of leukemia, the initial genetic hit often leads to abnormal
cell differentiation (Type II mutation), while subsequent mutations
may activate specific signaling pathways that are involved in cell
growth, such as the ras/MAP kinase pathway (Type I mutation)
[3,29,31]. Indeed, MLL-rearranged AML in neonatal bloodspots
was shown to be of prenatal origin, supporting the idea that MLL
rearrangement is one of the earliest events (first hit) in
leukemogenesis [32]. In this line, the effect of MLL-AF10 as the
first hit is thought to be differentiation arrest or the promotion of a
specific hematopoietic lineage, because two previous studies
demonstrated that MLL-AF10 expression in mouse HSCs results
in skewed myeloid hematopoiesis [21,22]. However, in human
HSCs, MLL-AF10 did not give rise to skewed hematopoiesis, but
Figure 4. Cooperation of MLL-AF10 with activated K-ras induced acute monoblastic leukemia. (A) Kaplan-Meier survival analysis of mice
receiving transplants of human HSCs transfected with EV (n=8), K-ras
G12V (n=12), MLL-AF10 (n=6), or MLL-AF10 plus K-ras
G12V (n=6) vectors. (B)
GFP and Venus expression in peripheral blood cells at the indicated weeks after transplantation with human HSCs co-transfected with the MLL-AF10
and K-ras
G12V genes. (C) May-Giemsa staining of the peripheral blood of mice engrafted with human HSCs co-transfected with the MLL-AF10 and K-
ras
G12V genes. Morphologic leukemia cells were found in the peripheral blood of these mice 50 days after transplantation. (D) Splenomegaly in the
MLL-AF10/K-ras
G12V mice. Spleens from mice engrafted with EV-transduced HSCs (left) and MLL-AF10/K-ras
G12V co-transduced HSCs (right) are shown.
The graph shows the mean 6 SD of the spleen weights from mice receiving transplants of EV-transduced HSCs (n=6) or of MLL-AF10/K-ras
G12V co-
transduced HSCs (n=6). ** represents p,0.01.
doi:10.1371/journal.pone.0037892.g004
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(Figures 1B and 2). Therefore, the biological impact of MLL-
AF10 as the first hit remains controversial.
The active mutation of ras genes is a known additional hit in
MLL-rearranged leukemia [27,29,33], and was so in our model.
The hematopoietic cells undergoing the first hit must survive until
the additional hit occurs during leukemogenesis. Since no HSCs
transdused with K-ras
G12V alone could be found in the BM of the
humanized mice even 25 weeks after transplantation (data not
shown), it is unlikely that the ras mutation was the first hit in our
model. Based on the present results, MLL-AF10 as the first hit
might alter the self-renewal regulation of HSCs because of its
promotion effect on multi-lineage hematopoiesis (Figures 1B and
2), and the HSCs (or leukemic precursor cells) might then receive
the additional hit (K-ras
G12V), leading to leukemia. A recent report
similarly demonstrated that co-transduction of BMI1 and Bcr-Abl
oncogenes in HSCs induced leukemia, in which ectopic expression
of BMI1 probably functioned as the additional hit, in NOD/SCID
mice [34]. Although further examination will be required to test
the additional hit hypothesis in leukemogenesis, our leukemia
model may be a useful and unique experimental system with
which to examine the multi-hit model of leukemogenesis.
Previous studies in which primary human leukemia cells were
transplanted into immunodeficient mice provided important
information about leukemia biology, in particular, about the
biological significance of leukemic stem cells. Ishikawa et al
recently demonstrated using NSG mice that the CD34
+CD38
- cell
population of the donor human leukemia most easily expands
in vivo and survives by associating with the osteoblast-like stroma
cells [9,10]. These findings shed light on how the leukemic stem
cells are maintained in vivo. However, evaluating the transplant-
ability or tumorigenic potential of each subpopulation from
primary leukemia into immunodeficient mice might be insufficient
to define leukemic stem cells. Intriguingly, a recent report
Figure 5. Immunophenotype and clonality of the MLL-AF10/K-ras-induced leukemia. (A) Frequencies of GFP
+/Venus
+ cells or human
CD45
+ cells in the BM, spleen, and liver at 8 weeks after transplantation with human HSCs co-transfected with the MLL-AF10 and K-ras
G12V genes were
examined by flowcytometric analysis. The flowcytometry data shown are representative of 6 to 8 mice per group in one representative experiment of
two (left). The average of %frequencies of the GFP
+ and Venus
+ cells in whole cells in the indicated organs is shown with the standard deviation
(right, upper; n=6). The absolute cell number of human CD45
+ cells in the indicated organs is shown with the standard deviation (right, lower; n=6).
(B) Representative RT-PCR results confirming the stable, long-term expression of the MLL-AF10 and Flag-K-ras
G12V transcripts in human hematopoietic
cells in the BM of mice 8 weeks after transplantation. (C) Lineage distribution of the GFP
+ and Venus
+ cells in the BM of a mouse engrafted with HSCs
expressing MLL-AF10 and activated K-ras. (D) Southern blot analysis of DNA prepared from the human blood cells in the spleen of mice receiving
transplants of MLL-AF10/K-ras
G12V co-transduced HSCs. Independent leukemia samples derived from two mice (lane 1; mouse 1 and lane 2; mouse 2)
were examined. DNA was digested with Bgl II and probed with an EGFP probe. M: marker.
doi:10.1371/journal.pone.0037892.g005
Figure 6. Pathological phenotypes of the leukemia. (A) Hematoxylin and eosin staining showing the infiltration of leukemic cells in the
indicated organs of mice engrafted with HSCs expressing the MLL-AF10 and K-ras
G12V genes compared to control mice. (B) Immunostaining by a
human CD45 mAb in the BM, spleen, and liver in mice engrafted with HSCs expressing the MLL-AF10 and K-ras
G12V genes.
doi:10.1371/journal.pone.0037892.g006
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the cells (putative non-stem cells) that were not transplantable in
NOD/SCID mice, which have NK cells, could easily survive and
expand, like stem cells, in NSG mice, which lack NK cells [35].
This indicates the possibility that the high transplantability of the
putative stem cell population as defined in the NOD/SCID mice
reflected simply their resistibility to NK-cell-killing. Therefore, the
observations in a certain transplantation model using immunode-
ficient mice may not necessarily reflect the physiological patho-
genesis of human leukemic stem cells.
In this context, the leukemia that arose in vivo from human
HSCs as demonstrated here may better reflect the physiological
biology of human leukemic stem cells. Furthermore, the primary
leukemia cells from different patients with leukemia showing even
the same phenotypic markers should be different. Thus, the in vivo
results from mice receiving transplants of different donor cells may
be difficult to interpret, even if the leukemia cells from individual
donors show the same phenotype. In contrast, the M5 leukemia
established here was uniform in terms of cell morphology,
symptoms (including selective tissue infiltration), and even survival
prognosis. Importantly, the high reproducibility by which the same
gene combination (MLL-AF10 and K-ras
G12V) induced the same
leukemia in individual mice may represent a considerable
advantage of these mice for the in vivo modeling of human
leukemia over previous models.
To examine whether the leukemia is transplantable in a second
recipient, we transplanted the leukemic cells from the spleen and
BM to healthy adult NOG mice at least 20 times. Unexpected, we,
however, could not find any GFP
+ cells in any second recipients
even 10 months after transplantation (data not shown). Since
GFP
+Venus
+ leukemic cells in the BM of the first hosts contained
less than 0.1% CD34
+CD38
- putative AML stem cells (data not
shown), leukemic stem cells might have lost their self-renewal
ability and been run out in the first host. To understand the
unexpected phenomenon, Further investigation will be required.
Over the last decade, the outcome in pediatric AML has
improved significantly, with up to 60% of children suffering from
MLL-rearranged AML currently surviving [3]. However, improv-
ing the outcome of pediatric AML using current treatment
protocols is hampered by treatment-related deaths and long-term
side effects. In addition, most patients with MLL-rearranged ALL
still indicate a poor prognosis. Therefore, to improve the outcome
in pediatric MLL-rearranged leukemia, the development of
leukemia-specific targeting drugs is an important strategy [36].
We hope that this newly established model using humanized mice
will contribute to future studies aimed at revealing the molecular
mechanisms for MLL-rearranged gene related leukemogenesis and
developing new therapies against MLL-related malignancies.
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